{"domain":"brainstorm-cell.com","status":"valid","tier":"listed","authority":47,"verified":false,"title":"BrainStorm Cell Therapeutics Inc.","summary":"BrainStorm Cell Therapeutics (OTCQB: BCLI) develops NurOwn®, an autologous MSC-NTF cell therapy for ALS, under an FDA-agreed Special Protocol Assessment.","country":"US","country_source":"ip","llms_txt":"https://brainstorm-cell.com/llms.txt","llms_full_txt":null,"last_checked":"2026-10-21T05:00:58.260Z","agent_terms":null,"categories":["healthcare","science-research"],"capabilities":[],"inferred_tags":["als","cell therapy","nurown","mesenchymal stem cells","clinical trials"],"audience":"business","agent_uses":["search_content"],"language":"en","platform_generated":false,"agent_summary":"BrainStorm Cell Therapeutics develops NurOwn, an autologous MSC cell therapy for ALS; the site holds its press release and news archive since 2014.","llms_txt_cached":"https://agentwebmap.com/v1/domain/brainstorm-cell.com/llms.txt","agentic":"informational","section_keys":["about","accessibility","careers","contact","email-alerts","events-and-presentations","investors","legal","newsroom","patients-caregivers","pipeline","science","sec-filings","sitemap"],"section_partial":false,"section_indexed_at":"2026-10-21T14:05:31.700Z"}